Sofinnova Investments Announces the Addition of Dr. Maha Radhakrishnan as Executive Partner

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug 6, 2024--

Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Maha Radhakrishnan, M.D. to the investment team as an Executive Partner.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806302382/en/

Dr. Maha Radhakrishnan, Executive Partner, Sofinnova Investments (Photo credit: Sofinnova Investments)

Dr. Radhakrishnan is an accomplished industry executive with over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.

Prior to joining Sofinnova, Dr. Radhakrishnan was Chief Medical Officer of Biogen, responsible for the worldwide medical function. She was also senior vice president and global head of medical, primary care business unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the function providing the medical strategy for diabetes and cardiovascular products and programs in development. Prior, she held several leadership roles at Bioverativ Inc., Bristol Myers Squibb, United Health Group, and Cephalon.

“Intentional and strategic growth of our team is core to our success, I believe Maha will be an exceptional asset to the Sofinnova team and portfolio as she brings decades of drug development expertise,” said Jim Healy, M.D., PhD., Managing Partner of Sofinnova Investments. “Her breadth of knowledge and operational experience will be invaluable in guiding portfolio companies, from clinical-stage drug development to large-scale commercialization to bring novel therapies to patients.”

“I am thrilled to join the Sofinnova Investments team. This is a team with an incredible track record of focusing on robust science and high unmet medical needs,” said Dr. Radhakrishnan. “We share a strong commitment to developing innovative therapeutics and advancing companies with a goal to create transformative value for patients. I look forward to leveraging my clinical, drug development, and commercialization experience to advance new and existing investment opportunities across Sofinnova’s portfolio.”

Dr. Radhakrishnan received her M.D. in internal medicine with honors from the People’s Friendship University in Moscow, Russia in 1995, as well as a master’s degree in Russian language.

About Sofinnova Investments

Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients. We invest in both private and public equity companies. Sofinnova actively partners with entrepreneurs across all stages of company formation, we are long-term investors with extensive scientific expertise, vast industry knowledge, and a track record of helping forge the path from drug development and navigating the regulatory process to company building and IPO or M&A.

Founded in 1976, Sofinnova has a long legacy of building what we believe are great companies in both the U.S. and Europe with approximately $3.7B in assets under management and committed capital as of 6/30/2024. For more information, please visit www.sofinnova.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240806302382/en/

CONTACT: Sofinnova Investments

Tiffany Davis

davis@sofinnova.com

Media Contact

Kimberly Ha

KKH Advisors

kimberly.ha@kkhadvisors.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH FINANCE RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Sofinnova Investments

PUB: 08/06/2024 08:00 AM/DISC: 08/06/2024 08:02 AM

http://www.businesswire.com/news/home/20240806302382/en